JP6276378B2 - ヒストンデメチラーゼ阻害剤 - Google Patents
ヒストンデメチラーゼ阻害剤 Download PDFInfo
- Publication number
- JP6276378B2 JP6276378B2 JP2016502219A JP2016502219A JP6276378B2 JP 6276378 B2 JP6276378 B2 JP 6276378B2 JP 2016502219 A JP2016502219 A JP 2016502219A JP 2016502219 A JP2016502219 A JP 2016502219A JP 6276378 B2 JP6276378 B2 JP 6276378B2
- Authority
- JP
- Japan
- Prior art keywords
- pyridine
- imidazol
- methyl
- preparation
- carbonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C[n]1c(-c2ccc(C3(CC3)C(F)(F)F)cc2)c(-c2nccc(C(*)=O)c2)nc1 Chemical compound C[n]1c(-c2ccc(C3(CC3)C(F)(F)F)cc2)c(-c2nccc(C(*)=O)c2)nc1 0.000 description 6
- QKLMRCKCBNWKDR-PZWSPEBMSA-N CC/C=C\[C@@H]1C(C(C2=CC=CC3=C[C@@H]23)(c2ccccc2)NCCN/C=C(/C(/C)=N/CC)\N)=C1 Chemical compound CC/C=C\[C@@H]1C(C(C2=CC=CC3=C[C@@H]23)(c2ccccc2)NCCN/C=C(/C(/C)=N/CC)\N)=C1 QKLMRCKCBNWKDR-PZWSPEBMSA-N 0.000 description 1
- MLEIKIABJFPWAE-UHFFFAOYSA-N CC[n]1cnc(-c2nccc(C#N)c2)c1 Chemical compound CC[n]1cnc(-c2nccc(C#N)c2)c1 MLEIKIABJFPWAE-UHFFFAOYSA-N 0.000 description 1
- MFMARIOXNZAIHE-UHFFFAOYSA-N CCc1ccccc1CC[n]1cnc(-c2cc(C(NC)=O)ccn2)c1 Chemical compound CCc1ccccc1CC[n]1cnc(-c2cc(C(NC)=O)ccn2)c1 MFMARIOXNZAIHE-UHFFFAOYSA-N 0.000 description 1
- IPBMKTJPRLOJDL-UHFFFAOYSA-N CN(C)CCC[n]1cnc(-c2nccc(C#N)c2)c1 Chemical compound CN(C)CCC[n]1cnc(-c2nccc(C#N)c2)c1 IPBMKTJPRLOJDL-UHFFFAOYSA-N 0.000 description 1
- QLURSABJFDGSCH-UHFFFAOYSA-N CN(CC[n]1cnc(-c2cc(C(OC)=O)ccn2)c1)Cc1ccccc1 Chemical compound CN(CC[n]1cnc(-c2cc(C(OC)=O)ccn2)c1)Cc1ccccc1 QLURSABJFDGSCH-UHFFFAOYSA-N 0.000 description 1
- WIGJIJYNPCKRAK-UHFFFAOYSA-N COC(c1cc(-c2c[n](Cc3cc(-c4ccccc4)ccc3)cn2)ncc1)=O Chemical compound COC(c1cc(-c2c[n](Cc3cc(-c4ccccc4)ccc3)cn2)ncc1)=O WIGJIJYNPCKRAK-UHFFFAOYSA-N 0.000 description 1
- AYQLIWPLWCHQJV-UHFFFAOYSA-N COc1c(CC[n]2cnc(C3NC=CC(C(O)=O)=C3)c2)cccc1 Chemical compound COc1c(CC[n]2cnc(C3NC=CC(C(O)=O)=C3)c2)cccc1 AYQLIWPLWCHQJV-UHFFFAOYSA-N 0.000 description 1
- BCSPEHKEKVRJOE-UHFFFAOYSA-N C[n]1c(-c(c(OCC2CC2)c2)ccc2F)c(-c2cc(C#N)ccn2)nc1 Chemical compound C[n]1c(-c(c(OCC2CC2)c2)ccc2F)c(-c2cc(C#N)ccn2)nc1 BCSPEHKEKVRJOE-UHFFFAOYSA-N 0.000 description 1
- RYHMPYHFLUZIAQ-UHFFFAOYSA-N C[n]1c(-c(cc2)ccc2N2CCCC2)c(-c2nccc(C(O)=O)c2)nc1 Chemical compound C[n]1c(-c(cc2)ccc2N2CCCC2)c(-c2nccc(C(O)=O)c2)nc1 RYHMPYHFLUZIAQ-UHFFFAOYSA-N 0.000 description 1
- OTBZGJHFGXDSHF-UHFFFAOYSA-N C[n]1c(-c(cc2)ccc2OC(F)(F)F)c(-c2nccc(C(O)=O)c2)nc1 Chemical compound C[n]1c(-c(cc2)ccc2OC(F)(F)F)c(-c2nccc(C(O)=O)c2)nc1 OTBZGJHFGXDSHF-UHFFFAOYSA-N 0.000 description 1
- LXCBCJKGQNJVQT-UHFFFAOYSA-N C[n]1c(-c(cc2)ccc2OCC2CC2)c(-c2nccc(C(OC)=O)c2)nc1 Chemical compound C[n]1c(-c(cc2)ccc2OCC2CC2)c(-c2nccc(C(OC)=O)c2)nc1 LXCBCJKGQNJVQT-UHFFFAOYSA-N 0.000 description 1
- RGGHHODGOGDPOE-UHFFFAOYSA-N C[n]1c(-c(cc2F)ccc2Cl)c(-c2nccc(C#N)c2)nc1 Chemical compound C[n]1c(-c(cc2F)ccc2Cl)c(-c2nccc(C#N)c2)nc1 RGGHHODGOGDPOE-UHFFFAOYSA-N 0.000 description 1
- MYEKGNIACAPRJV-UHFFFAOYSA-N C[n]1c(-c(cc2OCc3ccccc3)ccc2Cl)c(-c2nccc(C#N)c2)nc1 Chemical compound C[n]1c(-c(cc2OCc3ccccc3)ccc2Cl)c(-c2nccc(C#N)c2)nc1 MYEKGNIACAPRJV-UHFFFAOYSA-N 0.000 description 1
- ZAXOFLKXTQAQTR-UHFFFAOYSA-N C[n]1c(-c2ccc(cc[nH]3)c3c2)c(-c2nccc(C#N)c2)nc1 Chemical compound C[n]1c(-c2ccc(cc[nH]3)c3c2)c(-c2nccc(C#N)c2)nc1 ZAXOFLKXTQAQTR-UHFFFAOYSA-N 0.000 description 1
- INLYKPMFVOTAJW-UHFFFAOYSA-N C[n]1c(Br)c(-c2nccc(C(N=O)=O)c2)nc1 Chemical compound C[n]1c(Br)c(-c2nccc(C(N=O)=O)c2)nc1 INLYKPMFVOTAJW-UHFFFAOYSA-N 0.000 description 1
- OMRDLSVRGDLQSA-UHFFFAOYSA-N FC(C1C(Cl)=C(C[n]2cnc(-c3nccc(-c4n[nH]nn4)c3)c2)C=CC1)(F)F Chemical compound FC(C1C(Cl)=C(C[n]2cnc(-c3nccc(-c4n[nH]nn4)c3)c2)C=CC1)(F)F OMRDLSVRGDLQSA-UHFFFAOYSA-N 0.000 description 1
- OHROAERJATZXPV-UHFFFAOYSA-N N=C(C(C1)C=CN=C1c1c[n](C2CNCC2)cn1)O Chemical compound N=C(C(C1)C=CN=C1c1c[n](C2CNCC2)cn1)O OHROAERJATZXPV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783563P | 2013-03-14 | 2013-03-14 | |
| US61/783,563 | 2013-03-14 | ||
| PCT/US2014/026710 WO2014151945A1 (en) | 2013-03-14 | 2014-03-13 | Histone demethylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514159A JP2016514159A (ja) | 2016-05-19 |
| JP2016514159A5 JP2016514159A5 (OSRAM) | 2017-02-16 |
| JP6276378B2 true JP6276378B2 (ja) | 2018-02-07 |
Family
ID=51529949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502219A Expired - Fee Related JP6276378B2 (ja) | 2013-03-14 | 2014-03-13 | ヒストンデメチラーゼ阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US9133166B2 (OSRAM) |
| EP (1) | EP2969007B1 (OSRAM) |
| JP (1) | JP6276378B2 (OSRAM) |
| AU (1) | AU2014236711A1 (OSRAM) |
| CA (1) | CA2903081A1 (OSRAM) |
| ES (1) | ES2731773T3 (OSRAM) |
| WO (1) | WO2014151945A1 (OSRAM) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9133166B2 (en) * | 2013-03-14 | 2015-09-15 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| MX391865B (es) | 2014-07-03 | 2025-03-21 | Celgene Quanticel Res Inc | Inhibidores de demetilasa-1 especifica de lisina. |
| JP6660060B2 (ja) | 2014-09-16 | 2020-03-04 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| US9896436B2 (en) | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| JP2016089002A (ja) * | 2014-10-31 | 2016-05-23 | 出光興産株式会社 | ベンゾフラノチオフェン骨格を有するモノマー及びポリマー、及びそのポリマーを用いた有機薄膜太陽電池材料 |
| WO2016112251A1 (en) | 2015-01-09 | 2016-07-14 | Genentech, Inc. | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
| EP3313420B1 (en) | 2015-06-25 | 2024-03-13 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| WO2017143011A1 (en) * | 2016-02-16 | 2017-08-24 | Chrysalis, Inc. | Histone demethylase inhibitors |
| JP6970680B2 (ja) * | 2016-03-15 | 2021-11-24 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3246330A1 (en) | 2016-05-18 | 2017-11-22 | Istituto Europeo di Oncologia S.r.l. | Imidazoles as histone demethylase inhibitors |
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| EA201892375A1 (ru) | 2016-05-27 | 2019-08-30 | Джилид Сайэнс, Инк. | Способы лечения инфекций, вызываемых вирусом гепатита b |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CA3035346A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| EP3507288B1 (en) | 2016-09-02 | 2020-08-26 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| CN106543092B (zh) * | 2016-10-14 | 2019-05-17 | 华东师范大学 | 1,5-二芳香基-1,2,4-三氮唑类化合物及其制药用途 |
| EP4234691A3 (en) | 2016-10-14 | 2023-10-18 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| AR110768A1 (es) | 2017-01-31 | 2019-05-02 | Gilead Sciences Inc | Formas cristalinas de tenofovir alafenamida |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| JP7098748B2 (ja) | 2017-12-20 | 2022-07-11 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| US20210254006A1 (en) | 2018-06-06 | 2021-08-19 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| US12318403B2 (en) | 2019-03-07 | 2025-06-03 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides and prodrugs thereof |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| JP7237311B2 (ja) * | 2019-06-06 | 2023-03-13 | 京都府公立大学法人 | 化合物、医薬組成物、ｋｄｍ５ｃ阻害剤及び抗うつ剤 |
| NZ783169A (en) | 2019-06-25 | 2024-12-20 | Gilead Sciences Inc | Flt3l-fc fusion proteins and methods of use |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司（Us） | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
| US20230303599A1 (en) | 2020-08-07 | 2023-09-28 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2023338217A1 (en) | 2022-09-09 | 2025-04-03 | Innovo Therapeutics, Inc. | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2320730A1 (en) | 1998-12-23 | 2000-07-06 | Renhua Li | Thrombin or factor xa inhibitors |
| DE60133758T2 (de) | 2000-10-26 | 2009-07-02 | Amgen Inc., Thousand Oaks | Antiphlogistische mittel |
| US20040127733A1 (en) | 2002-10-31 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions |
| DE102004021779A1 (de) | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2007071653A1 (en) | 2005-12-19 | 2007-06-28 | Boehringer Ingelheim International Gmbh | Use of aminoalcohol derivatives for the treatment of overactive bladder |
| ATE532770T1 (de) | 2006-09-05 | 2011-11-15 | Kyowa Hakko Kirin Co Ltd | Imidazolderivat |
| JP2010524970A (ja) * | 2007-04-20 | 2010-07-22 | デシフェラ ファーマシューティカルズ，エルエルシー | 骨髄増殖性疾患及びその他の増殖性疾患の治療に有用なキナーゼ阻害剤 |
| GB0818907D0 (en) * | 2008-10-15 | 2008-11-19 | Isis Innovation | Histone lysine demethylase inhibitors |
| WO2011021209A1 (en) * | 2009-07-07 | 2011-02-24 | Portsmouth Technologies Llc | Histone deacetylase inhibitors |
| CU24077B1 (es) | 2009-11-10 | 2015-03-30 | Pfizer | DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA |
| WO2011089995A1 (ja) * | 2010-01-21 | 2011-07-28 | 公立大学法人名古屋市立大学 | ヒドロキサム酸誘導体及びそれを用いたｈｄａｃ８阻害剤 |
| GB201112607D0 (en) * | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
| CN102775368B (zh) * | 2011-05-10 | 2016-08-17 | 上海驺虞医药科技有限公司 | 一类噻唑类化合物及其制备方法和用途 |
| US9133166B2 (en) * | 2013-03-14 | 2015-09-15 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| JP6660060B2 (ja) | 2014-09-16 | 2020-03-04 | セルジーン クオンティセル リサーチ，インク． | ヒストンデメチラーゼ阻害剤 |
-
2014
- 2014-03-13 US US14/210,006 patent/US9133166B2/en active Active
- 2014-03-13 CA CA2903081A patent/CA2903081A1/en not_active Abandoned
- 2014-03-13 AU AU2014236711A patent/AU2014236711A1/en not_active Abandoned
- 2014-03-13 EP EP14767499.8A patent/EP2969007B1/en active Active
- 2014-03-13 WO PCT/US2014/026710 patent/WO2014151945A1/en not_active Ceased
- 2014-03-13 ES ES14767499T patent/ES2731773T3/es active Active
- 2014-03-13 JP JP2016502219A patent/JP6276378B2/ja not_active Expired - Fee Related
- 2014-03-13 US US14/774,338 patent/US9527829B2/en active Active
-
2015
- 2015-09-11 US US14/852,079 patent/US9701657B2/en active Active
-
2016
- 2016-11-17 US US15/354,044 patent/US9963441B2/en active Active
-
2017
- 2017-06-07 US US15/616,319 patent/US10273222B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170066739A1 (en) | 2017-03-09 |
| AU2014236711A1 (en) | 2015-09-17 |
| WO2014151945A1 (en) | 2014-09-25 |
| JP2016514159A (ja) | 2016-05-19 |
| US20160113914A1 (en) | 2016-04-28 |
| EP2969007B1 (en) | 2019-05-08 |
| CA2903081A1 (en) | 2014-09-25 |
| ES2731773T3 (es) | 2019-11-19 |
| EP2969007A1 (en) | 2016-01-20 |
| US9701657B2 (en) | 2017-07-11 |
| US9133166B2 (en) | 2015-09-15 |
| US9527829B2 (en) | 2016-12-27 |
| US20140275084A1 (en) | 2014-09-18 |
| US20170334879A1 (en) | 2017-11-23 |
| US20160122314A1 (en) | 2016-05-05 |
| US10273222B2 (en) | 2019-04-30 |
| US9963441B2 (en) | 2018-05-08 |
| EP2969007A4 (en) | 2016-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6276378B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6256771B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| KR102400920B1 (ko) | 리신 특이적 데메틸라제-1의 억제제 | |
| AU2013363957A1 (en) | Histone demethylase inhibitors | |
| KR20170048590A (ko) | 히스톤 데메틸라아제 억제제 | |
| JP6970680B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP2017529347A (ja) | ヒストンデメチラーゼ阻害剤 | |
| US9896436B2 (en) | Histone demethylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151026 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170107 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170309 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20171106 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171225 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180111 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6276378 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |